It is a rAAV2-based platform that delivers an RPE65 expression cassette to treat type 2 Leber Congenital Amaurosis (LCA), a recessive monogenetic retinal dystrophy caused by biallelic pathogenic mutation in the RPE65 gene [13]. Here, RPE65 is linked to Leber congenital amaurosis 2.